E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/10/2006 in the Prospect News Biotech Daily.

RBC puts Kos at sector perform

Kos Pharmaceuticals, Inc. was given a sector perform, average risk, rating with a $78 price target by RBC Capital Markets analyst Ken Trbovich after Niaspan revenue was $14 million better than expected due to a 20% price increase. The company reported earnings per share of $0.76 versus the analyst's estimate and street consensus of $0.57. Shares of the Cranbury, N.J.-based pharmaceutical company were up 16 cents, or 0.21%, at $77.31. (Nasdaq: KOSP)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.